Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.
Context Therapeutics Inc. reports developments as a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors. Its news centers on oncology programs including CTIM-76, a CLDN6 x CD3 bispecific antibody; CT-95, a MSLN x CD3 bispecific antibody; and CT-202, a Nectin-4 x CD3 bispecific antibody.
Recurring updates cover clinical and preclinical data, regulatory designations, scientific conference presentations, operating results, research and development spending, liquidity, investor-conference activity and equity-based employee inducement grants. CTIM-76 has received FDA Fast Track designation for platinum-resistant ovarian cancer, adding regulatory status to the company's solid-tumor development disclosures.
Context Therapeutics (Nasdaq: CNTX) has announced key appointments to support the development of its clinical-stage T cell engaging assets for solid tumors. Dr. Claudio Dansky Ullmann joins as Chief Medical Officer, bringing over 30 years of experience in oncology therapeutics development. Karen Andreas, M.S. is appointed as Vice President of Clinical Operations, with almost 20 years of biopharma experience.
These appointments come as Context advances its product candidates, CTIM-76 and CT-95, into Phase 1 clinical trials. The company is granting stock options to Dr. Dansky Ullmann and other new employees as inducement awards, subject to vesting conditions and Nasdaq listing rules.
Context Therapeutics, a biopharmaceutical company specializing in solid tumor treatments, has acquired CT-95, a potentially first-in-class mesothelin x CD3 bispecific antibody from Link Immunotherapeutics. This acquisition, announced on July 10, 2024, aligns with Context’s strategy to expand its pipeline of T cell engager assets. CT-95 has already received Investigational New Drug (IND) clearance from the U.S. FDA and is expected to begin Phase 1 trials in Q1 2025. The antibody targets mesothelin, prevalent in cancers like ovarian, lung, and pancreatic. Context plans to use its existing cash reserves to fund the acquisition and initial clinical trials.
Context Therapeutics Inc. reported on the FDA clearance of their IND application for a Phase 1 clinical trial of CTIM-76 and completed a $100 million financing round. They anticipate funding to last until 2028. The company showcased financial results for Q1 2024, emphasizing a decrease in R&D expenses and a net loss of $3.7 million for the quarter.
Context Therapeutics received FDA clearance for its IND application for a Phase 1 clinical trial of CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, focusing on gynecologic and testicular cancers. The Company aims to enroll the first patient by mid-2024.
Context Therapeutics Inc. announced a $100 million private placement with healthcare investors to advance medicines for solid tumors. The financing will extend the cash runway into 2028. The private placement is expected to close on May 6, 2024, and includes the sale of approximately 64.5 million shares of common stock at $1.55 per share.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.